首页> 外文期刊>Frontiers in Laboratory Medicine >The association between long noncoding RNA H19 and pathological features in cancers: A meta-analysis
【24h】

The association between long noncoding RNA H19 and pathological features in cancers: A meta-analysis

机译:长非编码RNA H19与癌症病理特征之间的关联:一项荟萃分析

获取原文
       

摘要

Purpose Long noncoding RNA (lncRNA) H19 has been reported to be up-regulated and down-regulated in numerous tumors, but the relevance of clinical pathological features is not established. So, meta-analysis was conducted to investigate the association between H19 expression and pathological features of cancers. Method The databases on PubMed, Web of Science, CNKI, and Wan Fang were searched for the related studies. 13 eligible studies were included with a total of 854 patients. Revman5.3 and Stata12.0 software were performed to analyze the data. Results The results suggested that the group of high H19 expression had a higher risk of poorly histological grade, clinical stage, deep tumor invasion (T2 stage or more), and was inclined to lymphatic metastasis, distant metastasis, and had a shorter survival time than the group of low H19 expression. Conclusion High expression of lncRNAH19 might act as a novel diagnostic biomarker and predict poor oncological outcomes of patients with cancers.
机译:目的据报道,在许多肿瘤中长非编码RNA(lncRNA)H19均被上调和下调,但尚未确定其临床病理特征的相关性。因此,进行了荟萃分析,以研究H19表达与癌症病理特征之间的关系。方法检索PubMed,Web of Science,CNKI和Wan Fang上的数据库以进行相关研究。纳入13项合格研究,总计854例患者。使用Revman5.3和Stata12.0软件分析数据。结果结果表明,高表达H19的组组织学分级差,临床分期,深部肿瘤浸润(T2期或更高)的风险更高,并且倾向于淋巴转移,远处转移,并且生存时间短于低H19表达的组。结论lncRNAH19的高表达可能是一种新型的诊断生物标志物,并预测癌症患者的肿瘤学结局较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号